Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 16, Issue 12, Pages 869-872
Hot Topics in Gastroenterology

Funding the New Biologics – Public Policy Issues in Drug Formulary Decision Making

Steven Lewis1,2

1Access Consulting Ltd, Saskatoon, Saskatchewan, Canada
2Centre for Health and Policy Studies, University of Calgary, Calgary, Alberta, Canada

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [4 citations]

The following is the list of published articles that have cited the current article.

  • Keith Bodger, “Economic implications of biological therapies for Crohn's disease: Review of infliximab,” PharmacoEconomics, vol. 23, no. 9, pp. 875–888, 2005. View at Publisher · View at Google Scholar
  • Russell D. Cohen, and Tojo Thomas, “Economics of the Use of Biologics in the Treatment of Inflammatory Bowel Disease,” Gastroenterology Clinics of North America, vol. 35, no. 4, pp. 867–882, 2006. View at Publisher · View at Google Scholar
  • Russell D. Cohen, “The pharmacoeconomics of biologic therapy for IBD,” Nature Reviews Gastroenterology & Hepatology, vol. 7, no. 2, pp. 103–109, 2010. View at Publisher · View at Google Scholar
  • Tojo Thomas, and Russell D Cohen, “Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies,” Expert Review of Gastroenterology & Hepatology, vol. 1, no. 1, pp. 101–112, 2014. View at Publisher · View at Google Scholar